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CD4
+CD25
+ regulatory T cells (Treg) are known to influence T cell responses to
tumours.Here wehaveexplored the roleof Tregininhibiting notonlyadaptive,butalso
innate immune responses to tumours. To this end we used a Fas ligand (FasL)-
expressing melanoma cell line in a mouse model. In this system, innate immunity is
sufficient to reject the tumour. All mice depleted of Treg and challenged with FasL-
expressing melanoma remained tumour-free. Investigation of the underlying cellular
effector mechanisms revealed that depletion of Treg enhanced an NK cell response
capable of tumour lysis. Furthermore, this initial innate immune response primed mice
to make an effective adaptive immune response leading to complete rejection of
challenge with the parental melanoma. Both antigen-specific antibody and CD4
+ Tcells
were implicated in protection via adaptive immunity. We conclude that removal of Treg
and vaccination with whole tumour cells expressing FasL activates multiple arms of the
immune system, leading to efficient tumour rejection. These findings highlight a novel
role for FasL in inducing innate immune responses that are normally inhibited by Treg
and uncover an adjuvant effect of FasL that can be used to stimulate tumour immunity
after depletion of Treg.
Supporting information for this article is available at
http://www.wiley-vch.de/contents/jc_2040/2007/36593_s.pdf
Introduction
Many studies in mouse models indicate that
CD4
+CD25
+ regulatory T cells (Treg) significantly
impact the development of anti-tumour immune
responses [1]. Moreover, Treg exhibiting suppressive
activity have been found within tumour-infiltrating
lymphocytes of cancer patients [2]. Accumulation of
CD25
+ regulatory cells within tumours correlates with
reduced survival of patients with ovarian cancer,
arguing for a critical role for Treg in disease progression
[3]. Treg identified in humans exhibit the same
phenotypic and functional characteristics as their
murine counterparts. These cells express the transcrip-
tion factor FoxP3 as well as high levels of CTLA-4 and
suppress the proliferation of conventional Tcells in vitro
[4]. Clinical trials are underway to test whether
depletion of Treg can improve immunity to ovarian
cancer [5].
Here we use a model of tumour rejection involving a
melanoma cell line expressing Fas ligand (B16FasL) to
study the effect of Treg on both innate and adaptive
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overexpression of FasL in the melanoma cell line B16
leads to enhanced rejection [6]. Similar results have
been obtained with other tumour cell lines genetically
manipulated to over express FasL, and rejection is
associated with the induction of marked inflammation
with extensiveneutrophil infiltration [7]. Recent studies
have elaborated upon this result and show that in this
system membrane-bound FasL mediates inflammation
[8], CXC chemokines are essential for the observed
neutrophil recruitment [9], and neutrophil apoptosis
mediated via FasL expression is crucial for the induction
of inflammation [10]. Of additional relevance, we
demonstrated previously that B16FasL-treated mice that
remained tumour free were able to reject a secondary
challenge with the parental tumour B16F10 via induc-
tion of an antibody response [6]. B16FasL is therefore a
well-characterised model of tumour immunity, invol-
ving an initial innate immune response followed by the
establishment of an adaptive immune response capable
of rejecting a secondarychallenge, and is therefore ideal
for the study of the inhibitory effect of Treg on tumour
immunity.
Although the above-cited studies provide an in-depth
characterization of the B16FasL model, none directly
addressed the cellular effector mechanisms bywhich the
tumour itself is eliminated. Here, we show that the
innate immune response is sufficient to mediate the
rejection of B16FasL by recruitment of NK cells capable
of tumour lysis. Furthermore, we show that depletion of
Treg enhances adaptive immune responses by uncover-
ing a previously undetectable CD4
+ Tcell response. The
information obtained will be useful in the design of
vaccine strategies aimed at inducing multiple arms of
the immune system and for monitoring anti-tumour
responses in clinical trials of Treg depletion.
Results
Innateimmuneresponses are critical for rejection
of FasL-expressing melanoma
Several studies, including our own previous work, have
shown that injection of mice with FasL-expressing
tumour cells induces an inflammatory response within
hours of injection [11–13]. In order to determine
whether innate immunity is sufficient for the rejection
of B16FasL, the cells were injected into both C57BL/6
(B6) and C57BL/6RAG
–/– (RAG
–/–) mice and tumour
growth monitored. Approximately 50% of mice in each
group rejected the tumour challenge, suggesting that
neither T nor B lymphocytes played an important role in
the rejection of B16FasL and that the innate immune
response was sufficient (Fig. 1A). We then determined
which type of innate immune cells was responsible for
this rejection by depleting neutrophils, macrophages
and NK cells in vivo prior to tumour inoculation
(Fig.1B). Macrophages and NK cells but not neutrophils
played a critical role in the rejection of B16FasL in B6
mice, as their depletion significantly inhibited rejection
(Fig.1C). However, in RAG
–/– mice only depletion of NK
cells significantly affected rejection, whereas depletion
of macrophages reduced the number of tumour-free
mice substantially but not to a statistically significant
level (Fig. 1D). These data highlight a role for innate
immune cells in B16FasL rejection and indicate that NK
cells do not have to interact with T cells in order to
mediate tumour rejection. However, to formally demon-
strate a role for these cells, we wished to carry out
functionalassays.Sinceisolationofsufficientviablecells
from the subcutaneous tumour site is difficult, we
established an in vivo peritoneal challenge model similar
to the one described by Hohlbaum et al. [8].
To identify the effector cells responsible for tumour
killing, B16FasL, control B16F10 cells or PBS were
injected into the peritoneum. The lavage was subse-
quently evaluated for its cellular composition and
capacity to lyse tumour cells in vitro. Both B16F10
and B16FasL, but not PBS, attracted macrophages
(20–25% of total cells in lavage) and NK cells
(7–10%) (data not shown). Strikingly, and as published
by Hohlbaum et al., only B16FasL attracted a large
number of neutrophils (50%) into the peritoneal cavity
as compared to 10% in B16F10- or PBS-treated mice
[13]. These numbersweresimilar inB6andRAG
–/–mice
(data not shown).
Cells obtained from the lavage of PBS-treated mice
did not efficiently lyse tumour cells ex vivo (data not
shown). However, cells isolated from B16FasL-chal-
lenged peritoneal lavage were able to lyse B16F10 and
B16FasL. We hypothesized that either NK cells or
neutrophils were eliminating the tumour cells. To
investigate this we depleted B6 mice in vivo with the
mAb PK136 that depletes NK1.1
+ cells or with the
neutrophil-depleting mAb RB6–8C5. In vivo depletion of
NK cells but notneutrophils decreased the exvivolysis of
the tumour by the peritoneal cells (Fig. 2A). Similarly,
depletion of NK cells but not of neutrophils ex vivo from
the peritoneal exudate completely abolished this killing
(Fig. 2B), also excluding the possibility that macro-
phages are a major player in tumour lysis. Since NK cells
are known to recognise both the absence of MHC class I
and anadditional stimulatorysignal through the NKG2D
receptor, we tested whether our tumour cell lines
express NKG2D ligands using an NKG2D-Fc fusion
protein or GITR-L-Fc followed by a fluorescently tagged
anti-human Ig Ab. Both B16F10 and B16FasL stained
positively with recombinant NKG2D-Fc and were
positive for the murine NKG2D ligand Rae-1
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MHC class I compared to spleen cells (Fig. 2C and data
not shown). We therefore concluded that NK cells are
recruited upon B16FasL inoculation and are the key
effector cells responsible for tumour lysis.
CD4
+CD25
+ regulatory cells inhibit tumour-
induced innate immune responses
Our hypothesis that Treg inhibit innate immune
responses was first formulated on the basis of an
observation made using parental B16F10 cells. In these
experiments RAG
–/– mice were injected with
CD4
+CD25
+ Treg cells or control CD4
+CD25
– cells,
both from naive mice, or PBS alone, followed by B16F10
tumour challenge. Although all mice grew tumours, we
observed that tumours grew more rapidly in mice that
had received Treg compared to mice that received the
control cell population or PBS (data not shown). Since
the results of this experiment strongly suggested that
Treg inhibit innate immune responses, we decided to
performproof of principle experiments using B16FasL to
address this point. B16FasL were selected for the
following reasons: i) B16FasL, as opposed to B16F10,
is rejected in RAG
–/– mice as efficiently as in B6 mice; ii)
the innate immune response to B16FasL is sufficient to
rejectthetumour(Fig.1);iii)wehaveidentifiedNKcells
as the main effector cell type mediating this innate
B16FasL immunity in both B6 and RAG
–/– mice.
We investigated this hypothesis by injecting RAG
–/–
mice with CD4
+CD25
+ or CD4
+CD25
– cells purified
from B6 mice, followed 1 day later by inoculation with
B16FasL. Tumours were monitored weekly for at least
100 daysin all mouse groups. Approximately50% of the
mice inoculated with CD4
+CD25
– cells or PBS rejected
the B16FasL inoculum. However, rejection was not
observed in any of the mice injected with CD4
+CD25
+
cells. Transfer of CD4
+CD25
– T cells had no effect on
tumour development (Fig. 3A). These data suggest that
CD4
+CD25
+ Treg inhibit elements of the innate
immune system, reducing their ability to mediate
tumour rejection.
To further characterise this effect, we investigated
whether tumour rejection can be improved by depleting
Treg in B6 mice with the CD25-specific mAb PC61.
Administration of 1 mg PC61 results in an approximate
4-fold reduction in the number of CD4
+CD25
+ cells and
an approximate 2-fold reduction in FoxP3
+ T cells for
Figure 1. The innate immune system plays a key role in rejection of FasL-expressing tumour cells. (A, C, D) Mice were inoculated
s.c. with B16FasL, and tumour growth was measured for a minimum of 50 days. Solid bars and hatched bars indicate numbers of
tumour-free mice and tumour-bearing mice, respectively, in (A) B6 and RAG
–/– mice, (C) B6 mice depleted of neutrophils,
macrophages or NK cells or left untreated (none) and (D) RAG
–/– mice depleted of macrophages or NK cells or left untreated (none).
Each experiment was performed on two separate occasions. The statistical analysis was performed using Fisher's exact test
contingency tables with Prism software. (B) Depletion of neutrophils (F4/80
–Gr-1
hi), macrophages (F4/80
hi) and NK cells (NK1.1
+)i n
B6 mice treated with RB6–8C5, Carrageenan or PK136, respectively, compared to control GL113-treated mice was evaluated by
FACS. FACS plots shown are representative of ten mice per group.
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are rejected in 50% of untreated mice, increasing to
100% once Treg are depleted. By contrast, no B16F10
melanoma rejection is observed unless Treg are
depleted, after which rejection rates are enhanced
significantly (Fig. 3C). Collectively these data indicate
that CD4
+CD25
+ Treg inhibit innate immune responses
that are capable of tumour rejection in both B6 and
RAG
–/– mice. Since NK cells were the only cell type
shown to be critical for tumour rejection in both B6 and
RAG
–/– mice, we postulated that Treg cells inhibit the
activity of B16FasL-induced NK cells.
Treg inhibit NK cell activity
To determine whether Treg inhibit tumour lysis by NK
cells, peritoneal cells were obtained from B16FasL-
injected mice. CD4
+CD25
+ cells or CD4
+CD25
– cells
purified from naive B6 mice were either left unstimu-
lated and added 4 h before the killing assay to the
peritoneal lavage or were stimulated with anti-CD3 Ab
andirradiatedAPC.Althoughanotherstudyshowedthat
Treg can inhibit NK killing of tumours using unstimu-
lated CD4
+CD25
+ cells [14], we only observed inhibi-
tion of NK cell killing when the CD4
+CD25
+ cells were
stimulated with anti-CD3 Ab and irradiated APC
(Fig. 4A). Similar findings were reported by Smyth et
al. [15]. These cells also inhibited proliferation of
CD4
+CD25
– cells in a conventional Treg suppression
assay (see Materials and methods). To confirm this
finding in vivo, we purified CD4
+CD25
+ cells or
CD4
+CD25
– cells and injected them concomitantly with
B16FasL tumour cells into the peritoneum of B6 mice.
The presence of Treg in vivo significantly inhibited ex
vivo lysis by the peritoneal exudate cells (Fig. 4B).
Conversely, when Treg were depleted in vivo, tumour
lysis ex vivo was increased (Fig. 4C). Taken together,
these data show that Treg suppress NK cell tumour lysis
in vivo and in vitro after stimulation with anti-CD3 Ab
andirradiated APC.Inadditiontothesuppressiveeffects
of the Treg on killing, we observed an approximate 2-
fold reduction of NK cell percentages in the peritoneal
lavagewhen RAG
–/–mice(Fig.4D,leftpanel)orB6mice
(Fig. 4D, right panel) were injected with CD4
+CD25
+ as
opposed to CD4
+CD25
– cells. Altogether, these results
suggest that in addition to a direct effect of Treg on the
killing capacity of NK cells, Treg also either inhibit
recruitment of NK cells to sites of inflammation or
promote death of NK cells.
Figure 2. NK cells recovered from the peritoneum of mice injected with B16FasL kill tumour cells in vitro. Peritoneal cells were
recovered18 h afteri.p.injectionofB16FasLandusedaseffectorsina
51Cr-releaseassayagainstB16F10targetcells(similarresults
wereobtained using B16FasL as target cells, data not shown) at different effector to target ratios. Data shown are the mean  SD of
five mice per group. (A) In vivo depletion of neutrophils or NK cells. (B) Prior to the killing assay, effectors were depleted in vitro of
neutrophils or NK cells or both. (C) B16F10 and B16FasL were immunostained for MHC class 1, Rae-1 and NKG2D ligands (open
histograms), evaluated by FACS and compared to recombinant protein/isotype controls (filled histograms). These stainings were
performed twice with similar results.
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CD25
+ regulatory cells
Having established that the innate immune response to
B16FasL was improved following removal of Treg, we
next sought to determine whether this might have an
effect on the adaptive immune response. To this end we
challenged mice vaccinated with either B16FasL or
B16F10 cells (from Fig. 3C) with the parental cell line
B16F10, which is not normally rejected. About 50% of
mice that received B16FasL or B16F10 and anti-CD25
rejected the B16F10 cells. Strikingly, all mice that
received B16FasL and anti-CD25 rejected the B16F10
challenge(Fig.5,2
ndchallenge), implyingan additiveor
synergistic effect between Treg depletion and adaptive
immunity elicited by tumour vaccination. This is in
accord with our previous observation that the secondary
responsetotheparentalB16F10tumour in mice injected
withB16FasLisduetoaThelper-dependentAbresponse
[6]: following depletion of Treg, inoculation of mice
with B16F10 cells results in stimulation of CD4
+ T cell
responses capable of tumour rejection in approximately
70% of vaccinated mice [16]. On the basis of these
results, we postulated that the improved rejection in
mice with vaccination combined with Treg depletion
was due to an improved Ab response, improved T cell
response or a complementary action of both arms of the
immune system. To identify the correlates of immunity,
serum, CD4
+ T cells or CD8
+ T cells obtained from
vaccinatedmiceweretransferredintonaivehosts,which
were then challenged with the parental cell line B16F10.
Tumours grew in all mice that received no serum or cells
and in all mice receiving CD8
+ Tcells purified from the
vaccinated mice (data not shown). Fig. 5 shows that
serum from B16FasL-vaccinated mice but not naive
mice, as observed previously [6], mediated rejection of
the parental tumour B16F10 in a proportion of the naive
recipient mice: 60% of mice remained tumour-free
(Fig. 6A), whereas upon adoptive transfer, CD4
+ Tcells
purified from the same mice could not protect from a
B16F10 challenge (Fig. 6D). Furthermore, serum from
unprimed mice depleted of Treg was not protective
(Fig.6B).However,allmiceremainedtumour-freewhen
CD4
+ T cells were transferred (Fig. 6E), as shown
Figure 3. CD4
+CD25
+ regulatory cells inhibit the innate rejection of B16FasL. (A) RAG
–/– mice were injected with either PBS (thin
solid line), 1  10
6 purified CD4
+CD25
– T cells (thick solid line) or 1  10
6 purified CD4
+CD25
+ T cells (short dashes) 1 day prior to
s.c. injection of B16FasL cells. Tumour growth was monitored over time. The number in parenthesis indicates the number of mice
per group. Similar results were obtained on two separate occasions with a minimum of six mice per group. (B) B6 mice were
injected i.p. with control Ab GL113 or anti-CD25 depleting Ab PC61. Spleens were harvested 3 days later and immunostained for
CD4, CD25 and FoxP3 and evaluated by FACS. Plots shown are representative of ten mice per group. Total numbers of CD4
+FoxP3
+
and CD4
+CD25
+ cells in the spleen are also given with a minimum of seven mice per group. (C) B6 mice were either depleted of
CD25
+ cells or not (GL113 isotype control) and then injected s.c. with parental B16F10 or B16FasL. Tumour growth was monitored
over 75 days. Tumour-free mice are indicated. This experiment was repeated five times with a minimum of eight mice per group.
The number of tumour-free mice in the experiment shown is indicated in parenthesis.
Anna Katharina Simon et al. Eur. J. Immunol. 2007. 37: 758–767 762
f 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eupreviously [16]. Finally, both CD4
+ T cells and serum
from mice vaccinated with B16FasL in the absence of
Tregpromoted60%ofmicetorejectB16F10(Fig.6C,F).
Collectively, these data indicate that tumour rejection
was more efficient in mice injected with B16FasL
following depletion of Treg due to stimulation of both
a protective Ab and a CD4
+ T cell response.
Discussion
It is emerging that one of the most promising human
applications of Treg is in tumour immunology, in large
part because depletion of Treg should prove easier than
ex vivo expansion and cell transfer for the treatment of
autoimmune disease. It is therefore extremelyimportant
tounderstand the implications of Treg depletion on both
the innate and adaptive responses to tumours. FasL-
transfected murine melanoma is ideally suited to study
Figure 4. CD4
+CD25
+ cells inhibit killing and attraction of NK cells in theperitoneal model. (A) B16FasL cells (2  10
6) were injected
into B6 mice, and 24 h later the peritoneum was lavaged and cells counted. Lavaged cells (10
5) were added to 10
45 1 Cr-labelled
B16F10 cells in the presence of 10
5 purified CD4
+CD25
+ or CD4
+CD25
– T cells. Controls included lavaged cells (effectors) alone and
CD4
+CD25
– cellswithout effectors.The supernatantwascollected 5 h laterandanalysedonabetacounter. Meanswere calculated
from triplicates. (B) CD4
+CD25
+ or CD4
+CD25
– cells (2  10
6) were injected i.p. concomitantly with 2  10
6 B16FasL. Peritoneal cells
wererecovered 18 h laterandused as effectorsin a killingassay (as above) against B16F10at different effector to target ratios. This
was repeated in a second experiment (three mice per group in each experiment). (C) B6 mice were depleted in vivo of CD25
+ cells,
NK cells or both CD25
+ cells and NK cells. Treatment with the Ab GL113 served as a control (no depletion). The mice were rested
until the depleting Ab PC61 had disappeared from the serum and were then injected i.p. with B16FasL cells. Peritoneal cells were
used as effectors cells as in (A). (D) NK1.1
+CD3
– cells were evaluated by FACS. Shown are two separate experiments: In the left
panel, recipient mice were RAG
–/– (n=2 per group), and in the right panel, recipient mice were B6. Data are representative of two
separate experiments with a minimum of five mice per group. Statistical analysis was performed using the two-tailed Mann-
Whitney test with Prism software (**p<0.01, *p<0.05).
Figure 5. The adaptive immune response to B16FasL is
inhibited by CD25
+ cells. Mice that remained tumour-free in
Fig. 3B were challenged s.c. with 2  10
5 B16F10 in the same
flank, and tumour growth was measured for another 50 days.
This experiment was repeated five times with a minimum of
eight mice per group.
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as it (in contrast to the untransfected tumour cell line)
induces an influx of inflammatory cells, which leads to
rejection of the FasL melanoma in the absence of
adaptive immunity [8,17]. We show herethat the innate
immune system is sufficient to reject B16FasL tumours,
since tumour cells were rejected as efficiently in RAG
–/–
mice as in wild-type B6 mice. Furthermore, rejection of
B16FasL in B6 mice requires NK cells and macrophages.
Macrophagesattracted tothe site of B16FasL inoculation
may promote tumour rejection directly through produc-
tion of inflammatory cytokines and recruitment of other
immunecells.Indeed,engagementofFas
+macrophages
with FasL has been shown to induce secretion of CC and
CXC chemokines, which act as chemoattractants for NK
cells that clearly play an important role in rejection of
B16FasL [9]. It is also possible that the cells, as shown by
others, secrete chemokines that attract Treg tothe site of
tumour, possibly promoting their death through inter-
actionwith FasL on thetumour cells. NK cells most likely
promote tumour rejection through direct cytolysis. In
the peritoneal model, recruited NK cells but not
neutrophils lysed the parental and FasL-transfected
melanomas. This is in contrast to a publication by Seino
et al. in which neutrophils from peritoneal exudates
elicited by injection of FasL-expressing lymphoma were
suspected to be directly cytotoxic against tumour cells
[7]; however, this was not directly demonstrated but
rather implied on the basis that the exudate contained
80 to 90% neutrophils [7]. Our findings are consistent
with a report by Igney et al. in which mice with a
deficiency in neutrophil cytotoxicity were injected with
FasL-expressing tumours, and the tumour growth rate
was the same as in wild-type mice [18].
One explanation for the ability of FasL expression to
help tumour rejection is preferential killing of Treg. We
performed a killing experiment using B16FasL or
recombinant crosslinked FasL, which indicated that
CD25
+ Treg are more susceptible to killing via Fas than
CD4
+CD25
– T cells (Supporting Information Fig. 1), as
shown by others [19, 20]. However, neither peritoneal
CD4
+CD25
+ cells nor CD4
+FoxP3
+ cells express Fas
(Supporting Information Fig. 2A), and their number is
not significantly different in B16FasL-induced lavage as
compared to naive lavage (Supporting Information
Fig. 2B), indicating that B16FasL does not preferentially
kill Treg. Finally, the data that we generated during the
course of the study indicate that whilst direct Fas-FasL
killing of the Treg may contribute to tumour rejection,
the main contribution to tumour rejection is via
depletion of Treg using the CD25-specific mAb PC61.
Two pieces of evidence support this claim: Firstly, 100%
of mice reject B16FasL after treatment with PC61
compared to approximately 50% of untreated mice.
Secondly, if rejection of B16FasL was largely based on
the increased susceptibility of CD4
+CD25
+ cells to FasL-
induced cell death, the induction of a CD4
+ T cell
response, which develops as a result of Treg depletion
[16], would be apparent in mice immunised with
B16FasL without administration of CD25-specific de-
pleting mAb. This CD4
+ T cell response, which is
essential for tumour rejection in 100% of the mice, is not
apparent unless the antibody is administered. Thus,
rejection of B16FasL is not solely based on increased
Figure 6. Both antibodyandCD4
+ cells mediateB16FasLtumour immunity in CD4
+CD25
+-depletedmice. Serum(A–C) or CD4
+ cells
(D–F) were transferred from mice vaccinated with B16FasL, depleted of CD25
+ cells or both into naive B6 mice, which were
subsequently challenged with B16F10. Each line represents tumour growth in an individual mouse, and the numbers in the lower
right corner indicate the percentage of tumour-free mice in each group. Similar results were obtained in five independent
experiments with a minimum of five mice per group.
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+CD25
+ cells to FasL-induced cell
death. As mentioned above, these data do not, however,
completely exclude a role for Treg killing by the tumour,
and it remains possible that expression of FasL on
tumour cellsmaypromotetumour immunity byFas-FasL
killing of Treg.
In support of our hypothesis that Treg inhibit innate
immune responses, we found that adoptive transfer of
CD4
+CD25
+ cells but not CD4
+CD25
– cells inhibited
tumour rejection in RAG
–/– mice. In vivo depletion of NK
cells abolished ex vivo tumour lysis by peritoneal lavage
cells, as did adoptive transfer of CD4
+CD25
+ cells,
whereas depletion of Treg increased tumour killing.
Together these data suggest that Treg impede the anti-
tumour NK cell response. In contrast to the findings of
Ghiringhellietal.[21]butsimilar tothoseofSmythetal.
[15], we were only able to demonstrate inhibition of NK
cell cytolytic activity in vitro after activating the purified
CD4
+CD25
+ cells with anti-CD3 Ab and irradiated APC.
Treg are believed to inhibit NKG2D-mediated NK cell
killing [15], and in accordance with this observation,
both tumour cell lines (B16F10 and B16FasL) used in
these experiments express the NK2GD ligand Rae-1
(Fig. 2C), in contrast to other studies in which NKG2D
ligands were transfected into tumour cells [14, 15]. The
studies of the effect of Treg on NK cells also demon-
strated that suppression by Treg could be inhibited with
mAb to block TGF-b [14, 15]. In our model, TGF-b does
not completely account for the suppressive effectof Treg
on NK cells, since neutralisation of TGF-b using the
TGF-b-specific neutralising mAb 1D11 [22] did not
increase killing within the peritoneal lavage, while
depletion of Treg did (data not shown). We did,
however, observe that neutralisation of TGF-b increased
NK cell and neutrophil recruitment into the peritoneum
following injection of tumour cells. The increase,
although not statistically significant, was consistent,
thus raising the possibility that secretion of TGF-b,
perhaps by Treg, impedes recruitment of NK cells and
neutrophils. Studies of NK cell migration following virus
infection support a role for MIP-1a, a chemokine whose
productionisdrivenbyTypeIinterferons(IFN)[23,24].
Indeed, we have previously shown that the ability to
reject B16FasL is impaired in MIP-1a-deficient mice [6],
a finding that may be attributable to defective NK cell
migration to the tumour site. With this in mind, we are
currently investigating whether Treg inhibit production
of Type I IFN or MIP-1a following inoculation of mice
with B16FasL cells.
InoculationofmicewithB16FasLfollowingdepletion
of Treg resulted in induction of long-term tumour
immunity in all injected mice. A subsequent analysis of
the injected mice revealed that enhanced tumour
immunity was due to the combined effects of both the
cellular and the humoral arm of the immune system. As
described previously, the induction of the antibody
response was dependent upon the expression of FasL,
whilst the induction of the CD4
+ T cell response was
dependent upon the removal of the inhibitory influence
of CD25
+ cells. We found no evidence that the quality
(isotype) or quantity of the antibody (binding avidity of
the serum for B16F10 and protection experiments with
decreasing amount of serum) improved following
depletion of Treg (data not shown) and therefore
concludedthatthere is no direct influence ofTregon the
antibody response against tumours in this model.
The observation that the combination of injection
with B16FasL and depletion of CD25
+ cells results in
induction of both humoral and cellular immune
responses implies that immune responses were gener-
ated against more than one, and possibly several,
antigenic targets. Sincetumour cells have been shown to
evade immune responses by downregulating expression
of antigens and/or MHC molecules, increasing the
number of antigens that the immune system targets
makes it more difficult for tumours to escape immune
recognition (reviewed in [25]). Use of whole tumour
cells, as described in this study, is therefore beneficial in
this respect. It is not yet clear whether the adaptive
immune responses described above are more efficiently
generated in the absence of Treg due to removal of their
direct inhibitory effect on T cells or due to removal of
their inhibitory effect on the innate immune system,
which acts as a bridge for the efficient generation of
adaptive immune responses. In light of our findings that
NK responses are generated more efficiently in the
absence of Treg, the second possibility is intriguing. A
recent report showed that activated NK cells are an
important early source of IFN-c for the priming of Th1
cells [26]. The authors of the study demonstrated that
some but not all adjuvants led to the recruitment of NK
cells into lymph nodes, where the cells promoted
induction of Th1 responses through IFN-c production.
It is therefore possible that FasL, previously shown by
ourselves and others to act as an adjuvant for DC
maturation [6, 27], also acts as an adjuvant that recruits
NK cells. This pathway may be amplified following Treg
depletion, thereby resulting in increased production of
IFN-c. This in turn may facilitate development of the
CD4
+ T cell response, which as observed in the model
described here, is capable of tumour rejection. The
possibilities described above are not mutually exclusive,
however,anditislikelythatbothpathwayscontributeto
the overall amplification of adaptive immune responses.
In summary, we have found that immunisation of
mice depleted of CD25
+ Treg with whole tumour cells
engineered to express FasL induces effective tumour
immunity in all vaccinated mice. This is due to the
combined effects of: 1) the pro-inflammatory properties
of FasL; 2) expression of a range of antigens by whole
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of CD25
+ cells on both innate and adaptive immune
responses. Such an approach, combined with the
transient removal of CD25
+ cells in patients, may
significantly improve the success of vaccination follow-
ing tumour resection.
Materials and methods
Mice and tumour cell lines
C57BL/6 (B6) and C57BL/6RAG
–/– (RAG
–/–) mice (bred at
Biomedical Services, Oxford or purchased from Harlan, UK)
were maintained in Biomedical Services, Oxford or Cardiff.
Mice aged 6–10 wks were used in all experiments. During
experimental procedures mice were housed in filter-top cages
in conventional facilities. The B16F10 and B16FasL cell lines
used for thesestudies havebeendescribedpreviously [6]. Mice
were inoculated s.c. with 10
5 or i.p. with 2  10
6 tumour cells.
All experiments were performed in accordance with Home
Office guidelines.
Antibodies
The hybridomas secreting anti-CD25 (PC61, rat IgG1 [28]), rat
anti-E.coli b-galactosidase (GL113, rat IgG1, isotype control),
anti-NK1.1 (PK136, mouse IgG2a [29]) and anti-Gr-1
(RB6–8C5, rat IgG2b [7]) mAb as well as the efficiency of
these mAb in depleting their respective cell subset have been
described previously. Hybridomas were grown in culture, and
mAb were purified by precipitation in saturated ammonium
sulphate. For experiments involving s.c. injection of tumour
cells, mice received 0.5 mg mAb PC61, GL113 and PK136
3 days and 1 day prior to tumour cell injection. Mice depleted
of neutrophils received 300lg mAb RB6–8C5 1 day prior to
injection of tumour cells and 1, 3, 5, and 7 days after tumour
cell injection. All antibodies were injected i.p. in volumes of
100–200 lL.Fordepletionofmacrophages, micewereinjected
i.p. with 1 mL autoclaved carrageenan [7] (resuspended at
2 mg/mL in PBS) 1 day prior to the injection of tumour cells
and 3 and 7 days after tumour cell injection. For experiments
involving i.p injection of tumour cells, mice were given 1 mg
mAb 1 day prior to injection of tumour cells.
Antibody staining and flow cytometry
Cells from mice depleted of an immune subset were stained
with the following fluorescently labelled Ab: NK1.1-PE, Gr-1-
PerCpCy5.5, F4/80-allophycocyanin, CD25-PE, CD4-Cy5 and
FoxP3-PE. The latter required samples to be fixed and
permeabilised prior to Ab staining. B16F10 and B16FasL were
stained with 10 lg/mL NKG2D-Fc or GITR-L-Fc (as a control).
Cells were also stained with anti-Rae-1 (goat IgG), anti-MHC
class I (mouse IgG1) or appropriate isotype controls.
Purification of CD4
+CD25
+ T cells
CD4
+CD25
+ T cells were purified by negative selection using
Dynabeads and subsequent positive selection using MACS
beads. Spleen and lymph node cell suspensions prepared from
naive B6 mice were resuspended at 10
8 cells/mL in HBSS
(Gibco) and mixed at a 2:1 vol:vol ratio with an Ab cocktail
containing 10 lg/mL rat anti-B220, anti-Mac-1, anti-CD8,
anti-MHCclassIIandanti-NK1.1inHBSS/0.1%BSAinorderto
enrich CD4
+ cells. After a 20 min incubation on ice, the cells
were washed twice in HBSS, and Dynabead-conjugated sheep
anti-rat IgG Ab (Dynal) was added at a ratio of 1 Dynabead per
spleen cell. After a further 20 min incubation at 4
C,
Dynabead-bound cells were magnetically separated according
to the manufacturer's instructions (Dynal). Dynabead-bound
cells were discarded, a quarter of the original number of
Dynabeads was added to the cells, and a second round of
negative selection was performed as above. Cells that were not
Dynabead-bound (enriched for CD4
+ cells) were subsequently
incubated with anti-CD25 Ab conjugated to PE (Miltenyi) and
purified using microbeads conjugated to anti-PE Ab according
to the manufacturer's instructions (Miltenyi). Alternatively,
CD4
+CD25
+ and CD4
+CD25
– cells were purified using the
Miltenyi purification kit. A purity of greater than 90%
CD4
+CD25
+ cells was obtained in all experiments.
Peritoneal model and killing assay
Mice were injected i.p. with 2  10
6 B16F10 or B16FasL cells.
The peritoneal lavage was collected 18 h later using PBS with
2 mM EDTA and 0.5% BSA. Cells were then either subjected to
FACS analysis or used as effectors in a
51Cr-release assay.
Briefly, targets were labelled with
51Cr, and effectors were
added at the indicated ratio for 4 h before the supernatant was
collected. Percent tumour lysis was calculated using the
following formula: [sample – background (no effectors)] /
[total lysis – background].
CD25
+ Treg suppression assay
CD4
+CD25
+ Treg from spleens and lymph nodes were purified
using the Miltenyi purification kit and stimulated for 18 h with
1 lm anti-CD3 and 10
5 irradiated CD4
– splenocytes. B16FasL
cells (2  10
6) were injected into B6 mice, and 24 h later the
peritoneum was lavaged and the cells counted. Lavaged cells
(10
5) were added to 10
4 B16F10 cells previously labelled with
51Cr in the presence of 10
5 purified CD4
+CD25
+ or
CD4
+CD25
– Tcells. Controls included lavaged cells (effectors)
aloneandCD4
+CD25
–cellswithouteffectors.Thesupernatant
was collected 5 h later and analysed on a beta counter. Means
were calculated from triplicates. To test whether CD25
+ Treg
were functional, a proliferation assay was performed in the
presence of Treg. Purified CD4
+CD25
+ were cultured in the
presence of 10
5 CD4
+CD25
– splenocytes, 1 lm anti-CD3 and
10
5 irradiated CD4
– splenocytes. Cells were incubated for
3 days and pulsed with [
3H]-thymidine for a further 18 h.
Means were calculated from triplicates. At suppressor/effector
ratios of 1:100, 1:10, 1:1 and 10:1, 10%, 38%, 59% and 82%
inhibition was observed, respectively.
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+ cells and serum
CD4
+ lymphocytes from spleens were purified by positive
selection using magnetic beads (Miltenyi Biotec) according to
the manufacturer's instructions. Purity of CD4
+ cells was
greater than 95%. Recipient mice were injected i.v. with
5  10
6 cellson the dayofpurification. Toobtain serum, blood
was clottedat 37
C for 1 h, keptat 4
C for at least 1 h and then
spun at 20 000  g for 10 min. Recipient mice received the
serum i.v. (200 lL). In all transfer experiments, mice were
inoculated the following day with tumour cells.
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